

# Voon H Ong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/226551/publications.pdf>

Version: 2024-02-01

84  
papers

2,520  
citations

293460

24  
h-index

232693

48  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2946  
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 378-391.	2.9	19
2	Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 781-786.	0.9	7
3	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1948-1956.	0.9	6
4	Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features. <i>Journal of Rheumatology</i> , 2022, 49, 544-546.	1.0	1
5	Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination. <i>Journal of Autoimmunity</i> , 2022, 128, 102812.	3.0	12
6	P229â€fIntegrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	P227â€fMolecular and functional characterisation of distinct resident and migratory skin fibroblast populations in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
8	The Yin and Yang of IL-17 in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	20
9	Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	11
10	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. <i>Respirology</i> , 2021, 26, 461-468.	1.3	30
11	High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 849-854.	0.9	10
12	Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins. <i>Rheumatology Advances in Practice</i> , 2021, 5, raa083.	0.3	7
13	Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. <i>Rheumatology</i> , 2021, 60, 3945-3946.	0.9	9
14	P151â€fSelf-assessment of scleroderma skin thickness: development and evaluation of the PASTUL questionnaire. <i>Rheumatology</i> , 2021, 60, .	0.9	0
15	P154â€fHigh-density proteomic analysis of skin blister fluid and plasma in systemic sclerosis identifies local and systemic differences for key proteins. <i>Rheumatology</i> , 2021, 60, .	0.9	1
16	P157â€fPotential benefit of intravenous immunoglobulin in connective tissue disease associated interstitial lung diseases. <i>Rheumatology</i> , 2021, 60, .	0.9	0
17	O18â€fIntegrated molecular analysis of systemic sclerosis skin and blood shows significant differences between major autoantibody subgroups. <i>Rheumatology</i> , 2021, 60, .	0.9	0
18	Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertension. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 134, 105961.	1.2	9

#	ARTICLE	IF	CITATIONS
19	PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 819-820.	0.5	4
20	P21â€fMy eye was cloudy at first and I can see it is melting away!. <i>Rheumatology Advances in Practice</i> , 2021, 5, .	0.3	2
21	Using Autoantibodies and Cutaneous Subset to Develop Outcomeâ€Based Disease Classification in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 465-476.	2.9	123
22	Defining genetic risk factors for scleroderma-associated interstitial lung disease. <i>Clinical Rheumatology</i> , 2020, 39, 1173-1179.	1.0	12
23	Systemic sclerosis in pregnancy. <i>Obstetric Medicine</i> , 2020, 13, 105-111.	0.5	10
24	P151â€fForced vital capacity in patients with systemic sclerosis associated pulmonary fibrosis: predictors of meaningful decline. <i>Rheumatology</i> , 2020, 59, .	0.9	0
25	P152â€fSkin score trajectory associates with survival and pulmonary outcome in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020, 59, .	0.9	0
26	P154â€fStage and subset specific profiles of fibrogenesis highlighted through analysis of serum markers across the scleroderma spectrum. <i>Rheumatology</i> , 2020, 59, .	0.9	0
27	P156â€fUnderstanding the associations and impact of severe gastrointestinal involvement in systemic sclerosis: a structured approach. <i>Rheumatology</i> , 2020, 59, .	0.9	0
28	P155â€fCo-existence of scleroderma hallmark autoantibodies associates with distinct clinical phenotype. <i>Rheumatology</i> , 2020, 59, .	0.9	0
29	Scleroderma mimics â€ Clinical features and management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101489.	1.4	12
30	Improving access to digital ulcer care through nurseâ€led clinic: a service evaluation. <i>Musculoskeletal Care</i> , 2020, 18, 92-97.	0.6	3
31	Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2020, 8, 226-227.	5.2	2
32	Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1010-1013.	4.8	9
33	Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis. <i>Journal of Rheumatology</i> , 2020, 47, 1668-1677.	1.0	16
34	News and failures from recent treatment trials in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2020, 7, 242.	1.3	7
35	226â€fDisease-specific autoantibodies associate with remarkably different risk of development of significant lung fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
36	133â€fCoexistent tophaceous gout and calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
37	E074â€fDeveloping a molecular classifier for scleroderma spectrum disorders to augment clinical categorisation. <i>Rheumatology</i> , 2019, 58, .	0.9	1
38	E080â€fTwo cases of rapidly progressive diffuse cutaneous systemic sclerosis treated with autologous haematopoietic stem cell transplant. <i>Rheumatology</i> , 2019, 58, .	0.9	0
39	O17â€fSystemic sclerosis fibroblasts show defective activation by coagulation factor XIII in vitro: implications for impaired wound healing in SSc. <i>Rheumatology</i> , 2019, 58, .	0.9	0
40	225â€fDisease duration and autoantibodies determine distinct skin score trajectories in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
41	Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis. <i>Clinical Immunology</i> , 2019, 199, 18-24.	1.4	8
42	Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency. <i>BMJ Case Reports</i> , 2019, 12, e223180.	0.2	7
43	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
44	Functional and phenotypic heterogeneity of Th17 cells in health and disease. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13032.	1.7	31
45	Changes in macrophage transcriptome associate with systemic sclerosis and mediate <i>GSDMA</i> contribution to disease risk. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 596-601.	0.5	60
46	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
47	Association of Defective Regulation of Autoreactive Interleukinâ€6â€Producing Transitional B Lymphocytes WithâDisease in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 450-461.	2.9	33
48	199â€fFrequency and clinical association of rare antibodies in a large connective tissue disease cohort. <i>Rheumatology</i> , 2018, 57, .	0.9	0
49	206â€fProton pump inhibitor use is associated with calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
50	i127â€fThe future: targeting cytokines and signaling pathways: recent and ongoing clinical trials. <i>Rheumatology</i> , 2018, 57, .	0.9	0
51	O13â€fA simple classification of systemic sclerosis using subset and autoantibodies can discriminate well between distinct outcome groups. <i>Rheumatology</i> , 2018, 57, .	0.9	0
52	O16â€fA study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design. <i>Rheumatology</i> , 2018, 57, .	0.9	1
53	205â€fSerum tryptophan and kynurenine levels are altered in systemic sclerosis patients and show distinct clinical and autoantibody associations suggesting potential role in pathogenesis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
54	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.0	33
56	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 170-174.	1.0	27
57	Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky002.	0.3	15
58	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinat clinical trial in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1362-1371.	0.5	122
59	Severe gangrene in a patient with anti-RNP positive limited cutaneous systemic sclerosis/rheumatoid arthritis overlap syndrome caused by vasculopathy and vasculitis. <i>European Journal of Rheumatology</i> , 2018, 5, 269-271.	1.3	2
60	Development of systemic sclerosis in transgender females: a case series and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 50-52.	0.4	5
61	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
62	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
63	Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 237-264.	2.9	41
64	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, 912-921.	0.9	77
65	The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 401-423.	2.9	56
66	THE DISTINCTIVE CLINICAL PHENOTYPE OF ANTI-CENTROMERE ANTIBODY-POSITIVE DIFFUSE SYSTEMIC SCLEROSIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
67	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. <i>Arthritis Research and Therapy</i> , 2017, 19, 156.	1.6	14
68	BSR and BHPR guideline for the treatment of systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 1906-1910.	0.9	147
69	Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 115-119.	0.9	62
70	N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 122-128.	0.4	2
71	UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 106-109.	0.4	13
72	Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 2015-2024.	0.9	108

#	ARTICLE	IF	CITATIONS
73	Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S168-70.	0.4	10
74	Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 1625-1635.	2.9	354
75	Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 435-446.	1.0	226
76	Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1235-1242.	0.5	199
77	Scleroderma and related disorders: 223. Long Term Outcome in a Contemporary Systemic Sclerosis Cohort. <i>Rheumatology</i> , 2011, 50, iii129-iii137.	0.9	0
78	Clinical and Serological Hallmarks of Systemic Sclerosis Overlap Syndromes. <i>Journal of Rheumatology</i> , 2011, 38, 2406-2409.	1.0	110
79	Innovative therapies for systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 264-272.	2.0	36
80	Cross-talk between MCP-3 and TGF $\beta$ 2 promotes fibroblast collagen biosynthesis. <i>Experimental Cell Research</i> , 2009, 315, 151-161.	1.2	27
81	Management of systemic sclerosis. <i>Clinical Medicine</i> , 2005, 5, 214-219.	0.8	6
82	Monocyte Chemoattractant Protein-3 (Mcp-3) as a Mediator of Fibrosis in Scleroderma. <i>Clinical Science</i> , 2003, 104, 13P-13P.	0.0	0
83	Expression and Function of Monocyte Chemoattractant Protein-3 (MCP-3) in Scleroderma. <i>Clinical Science</i> , 2003, 104, 47P-47P.	0.0	0
84	Association of Anti-PM/SCL Antibody with Risk of Malignancy in Scleroderma. <i>Rheumatology</i> , 0, , .	0.9	0